![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1420203
ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀå : Áö¿ªº° ºÐ¼® - ¿øÀκ°, °Ë»ç À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, ¿¹Ãø(-2028³â)North America Endothelial Dysfunction Market Forecast to 2028 - Regional Analysis - by Cause, Test Type, and End User |
ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀå ±Ô¸ð´Â 2022³â 9¾ï 5,183¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022-2028³â ¿¬Æò±Õ 4.6% ¼ºÀåÇÏ¿© 2028³â¿¡´Â 12¾ï 4,730¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.
½ÉÇ÷°ü Áúȯ Áõ°¡·Î ºÏ¹Ì ³»ÇÇ ±â´É ºÎÀü ½ÃÀå ¼ºÀå ÃËÁø
¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ½ÉÇ÷°ü Áúȯ(CVD)Àº Àü ¼¼°è ÁÖ¿ä »ç¸Á ¿øÀÎ Áß ÇϳªÀ̸ç, ¸Å³â 3,000¸¸ ¸íÀÌ ³úÁ¹ÁßÀ» °æÇèÇϰí ÀÖÀ¸¸ç, CVD¿¡´Â ³úÇ÷°ü Áúȯ, °ü»óµ¿¸Æ Áúȯ, ·ù¸¶Æ¼½º¼º ½ÉÀå Áúȯ, °ü»óµ¿¸Æ Áúȯ(CAD) µîÀÌ Æ÷ÇԵ˴ϴÙ. Áß °¡Àå ÈçÇÑ ÁúȯÀ¸·Î °ü»óµ¿¸Æ ³»ÇÇÇϰ¿¡ ÁöÁú°ú ¸é¿ª¼¼Æ÷ÀÇ ÃàÀû, Áï Á׻󵿸ưæÈÁõÀ» Ư¡À¸·Î ÇÕ´Ï´Ù. Ç÷°ü ³»ÇÇÀÇ ¿°Áõ ¹ÝÀÀÀÌ °ü¿©Çϸç, CAD´Â Á׻󵿸ưæÈ·Î ÀÎÇÑ °ü»óµ¿¸Æ ³»°ÀÇ ÇùÂø, °æ·Ã, Æó»öÀ¸·Î ÀÎÇÑ ½É±ÙÀÇ ÇãÇ÷, Àú»ê¼ÒÁõ, ±«»ç°¡ Ư¡ÀÔ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î »ç¸Á ¿øÀÎ 1À§·Î ²ÅÈü´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â 6,000¸¸ ¸í ÀÌ»óÀÇ ¿©¼º(44%)ÀÌ ½ÉÀåÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. ½ÉÀ庴Àº ¹Ì±¹ ¿©¼ºÀÇ »ç¸Á ¿øÀÎ Áß 1À§À̸ç, ¿¬·É¿¡ °ü°è¾øÀÌ ¹ßº´ÇÒ ¼ö ÀÖÀ¸¸ç, 2021³â¿¡´Â 31¸¸661¸íÀÇ ¿©¼º »ç¸ÁÀÚ, Áï ¿©¼º »ç¸ÁÀÚ 5¸í Áß 1¸íÀÌ ½ÉÀ庴À¸·Î »ç¸ÁÇß½À´Ï´Ù.
¹Ì±¹½ÉÀåÇùȸ¿¡ µû¸£¸é, ¹Ì±¹ ¼ºÀÎÀÇ °ÅÀÇ Àý¹ÝÀÌ ½ÉÇ÷°ü ÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, 2035³â±îÁö ¹Ì±¹ Àα¸ÀÇ 45.1%¿¡ ÇØ´çÇÏ´Â 1¾ï 3õ¸¸ ¸í ÀÌ»óÀÌ ½ÉÇ÷°ü ÁúȯÀ» ¾ÎÀ» °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼ ³»ÇDZâ´ÉÀå¾Ö·Î ÀÎÇÑ ½ÉÇ÷°ü ÁúȯÀÇ ³ôÀº À¯º´·üÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀå °³¿ä
ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚÀÇ ÁÖ¿ä 3°³±¹À» ±âÁØÀ¸·Î ºÐ¼®µË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå È®´ë´Â ½ÉÀ庴 À¯º´·ü Áõ°¡¿Í ½ÉÀ庴ÇÐ ÀÎÆ÷¸Åƽ½º¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¹Ì±¹Àº CAD ºÎ´ã Áõ°¡, Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó, ÷´Ü ³»ÇÇ ±â´É ºÎÀü Ä¡·áÁ¦ ¹× ÀåÄ¡ °³¹ßÀ» À§ÇÑ R&D Ȱµ¿ µîÀÇ ¿äÀÎÀ¸·Î ºÏ¹Ì ³»ÇÇ ±â´É ºÎÀü ½ÃÀå¿¡¼ °¡Àå Å« ±Ô¸ð¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀå ¸ÅÃâ ¹× 2028³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)
ºÏ¹Ì ³»ÇÇ ±â´É ºÎÀü ½ÃÀå ¼¼ºÐÈ
ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀåÀº ¿øÀÎ, °Ë»ç À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.
¿øÀκ°·Î ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀåÀº °íÇ÷¾Ð, °íÄÝ·¹½ºÅ×·ÑÇ÷Áõ, ºñ¸¸, ´ç´¢º´, º£Ã¼Æ®º´, ±âŸ·Î ±¸ºÐµÇ¸ç, 2022³â ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀå Á¡À¯À²Àº °íÇ÷¾Ð ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.
°Ë»ç À¯Çü¿¡ µû¶ó ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀåÀº ħ½ÀÀû °Ë»ç¿Í ºñħ½ÀÀû °Ë»ç·Î ±¸ºÐµË´Ï´Ù. ħ½ÀÀû °Ë»ç ºÎ¹®Àº 2022³â ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀå Á¡À¯À²À» Å©°Ô À¯ÁöÇß½À´Ï´Ù. ºñħ½ÀÀû °Ë»ç ºÎ¹®Àº À¯µ¿ ¸Å°³ È®Àå, ¸»Ãʵ¿¸Æ Åä³ë¸ÞÆ®¸®(PAT), Á¤¸Æ Æó»ö Àü»êÈ ´ÜÃþ ÃÔ¿µ, ¼øÈ¯ ¸¶Ä¿ ¹× ±âŸ·Î ¼¼ºÐȵ˴ϴÙ.
ÃÖÁ¾ »ç¿ëÀÚº°·Î ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀåÀº º´¿ø, Áø´Ü¼¾ÅÍ, Ŭ¸®´Ð ¹× ±âŸ·Î ºÐ·ùµÇ¸ç, 2022³â ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀå Á¡À¯À²Àº º´¿ø ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î º¸¸é ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹Àº 2022³â ºÏ¹ÌÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
ZOLL Medical Corp, Lawrence Berkeley National Laboratory, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, Medizinische Messtechnik GmbH µîÀÌ ÀÌ Áö¿ªÀÇ ³»ÇDZâ´ÉÀå¾Ö ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷µéÀÔ´Ï´Ù.
The North America endothelial dysfunction market is expected to grow from US$ 951.83 million in 2022 to US$ 1,247.30 million by 2028. It is estimated to grow at a CAGR of 4.6% from 2022 to 2028.
Increasing Incidences of Cardiovascular Diseases Fuels North America Endothelial Dysfunction Market
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are among the leading causes of death worldwide, and ~30 million people experience a stroke each year. CVDs include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and coronary artery disease (CAD). CAD is the most common disease among all cardiovascular diseases, and it is characterized by the accumulation of lipids and immune cells in the subendothelial space of the coronary arteries or atherosclerosis. It involves the inflammatory response of the vascular endothelium. CAD is characterized by ischemia, hypoxia, or necrosis of the myocardium resulting from narrowing, spasm, or obstruction of the coronary artery lumen by atherosclerosis. It has become the leading cause of death worldwide. According to the Centers for Disease Control and Prevention (CDC), over 60 million women (44%) in the US suffer from some form of heart disease. Heart disease is the leading cause of death among women in the US and can affect women of any age. In 2021, it caused 310,661 deaths among women, i.e., nearly one in five female deaths.
According to the American Heart Association, almost half of all adults in the US suffer from a type of CVD. Over 130 million people, i.e., 45.1% of the US population, are projected to suffer from a type of CVD by 2035. Therefore, the high prevalence of cardiovascular diseases due to endothelial dysfunction drives the market.
North America Endothelial Dysfunction Market Overview
The North American endothelial dysfunction market is analyzed on the basis of three major countries: the US, Canada, and Mexico. The market expansion in the region can be attributed to an increase in the incidence of cardiac diseases and rising investments in cardiology informatics. The US holds the largest size of the endothelial dysfunction market in North America owing to factors such as the increasing burden of CAD, established healthcare infrastructure, and R&D activities undertaken to develop advanced endothelial dysfunction drugs and devices.
North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
North America Endothelial Dysfunction Market Segmentation
The North America endothelial dysfunction market is segmented into cause, test type, end user, and country.
Based on cause, the North America endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment registered the largest North America endothelial dysfunction market share in 2022.
Based on test type, the North America endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger North America endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.
Based on end user, the North America endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest North America endothelial dysfunction market share in 2022.
Based on country, the North America endothelial dysfunction market is segmented into the US, Canada, and Mexico. The US dominated the North America endothelial dysfunction market in 2022.
ZOLL Medical Corp, Lawrence Berkeley National Laboratory, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.